A $50 path to GLP-1 drugs on Medicare

Medicare has long declined to cover drugs taken purely for weight loss, which left the popular GLP-1 medications out of reach for many beneficiaries who wanted them for that reason. That changes, on a limited and temporary basis, on July 1, 2026. Under a CMS demonstration called the Medicare GLP-1 Bridge, eligible Part D members can get certain GLP-1 drugs for a fixed copay of $50 a month, running through December 31, 2027. At launch the covered list includes all formulations of Wegovy and Foundayo and the KwikPen formulation of Zepbound, with the program aimed at people who want the medication to reduce excess weight or keep weight off. Eligibility is not automatic. A provider has to confirm that a beneficiary meets specific body-mass-index thresholds and has a qualifying health condition, the kind the agency lists such as heart failure, high blood pressure, chronic kidney disease, prediabetes, or a history of cardiovascular trouble, and a prior authorization is part of the process. Here is the piece that is easy to miss, and the reason a plain explanation matters. The Bridge runs outside the normal Part D benefit. The $50 you pay each month does not count toward your Part D deductible and does not count toward the annual out-of-pocket cap that otherwise protects you once your drug spending is high. So for someone already managing other expensive prescriptions, the $50 is a separate line, not a step toward the ceiling. The program is also a demonstration, which means it is time-limited by design and is meant to test an approach, not to settle the larger question of whether Medicare should cover these drugs for weight loss permanently. For a shopper the takeaway is steadying rather than hyped: this is a real new option for a specific group of people, it has a clear price and clear conditions, and it is worth asking a doctor whether you qualify before assuming either that you do or that you do not.